{"nctId":"NCT00694122","briefTitle":"Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon","startDateStruct":{"date":"2005-06"},"conditions":["Type 1 Diabetes","Dawn Phenomenon"],"count":27,"armGroups":[{"label":"Glargine (Lantus) insulin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Lantus (glargine)"]},{"label":"NPH insulin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Lantus (glargine)"]}],"interventions":[{"name":"Lantus (glargine)","otherNames":["Lantus (glargine): Sanolfi Aventis","NPH: Eli Lilly"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Written informed consent obtained prior to performing screening evaluations.\n* Male or female, 18 yrs or older.\n* Diagnosis of type 1 diabetes made 5 years prior to screening visit.\n* A1C \\> 6.0% and 9.0% at screening visit.\n* Body Mass Index (BMI) 35 kg/m2 at screening visit.\n* Documented undetectable C-Peptide\n* Ability to follow instructions for Continuous Glucose Monitoring System (CGMS).\n* Multiple daily injection participants on at least 3 injections per day. May be treated with NPH or glargine.\n\nExclusion Criteria:\n\n* Pregnant or lactating females, or females planning to become pregnant during the study or not using an acceptable method of contraception. Females of childbearing potential must have a negative pregnancy test at Visit 3 and Visit 5. Females who become pregnant during the study will be discontinued.\n* Type 2 diabetes.\n* Two or more severe hypoglycemic episodes (requiring assistance) within six months of Screening.\n* Drugs known to affect glycemia (eg. steroids, beta blockers) or conditions that are likely to require steroid therapy or cause metabolic instability in the next 6 months.\n* History of allergy or intolerance to NPH or glargine.\n* History of hypoglycemia unawareness i.e. no warning symptoms accompanying low (\\<50 mg/dl) blood glucose levels.\n* Unable and/or unlikely to comprehend and/or follow the study protocol (including self blood glucose monitoring, CGMS).\n* Currently using an insulin pump.\n* Pituitary disorder (Acromegaly, Cushing's, Hypothyroidism etc.) or tumor.\n* Two or more severe hypoglycemic episodes (requiring assistance) within six months of Screening.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Blood Glucose Area Under the Curve (AUC)","description":"Cumulative sum of repeatedly measured blood glucose values (mg/dl) beginning at 22:00, then hourly till 08:00. Participants were monitored during two overnight sampling periods. One overnight was while the participant was on neutral protamine Hagedorn (NPH) insulin as the long acting insulin; the other overnight was glargine (Lantus) insulin as the the long acting insulin.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1673.33","spread":"760.7"},{"groupId":"OG001","value":"1395","spread":"384.9"}]}]}]},{"type":"SECONDARY","title":"Insulin Dose","description":"NPH or glargine (Lantus) was given at 22:00 to provide blood glucose coverage during the overnight hours.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.2","spread":"11.7"},{"groupId":"OG001","value":"20.7","spread":"10.0"}]}]}]},{"type":"SECONDARY","title":"Cortisol","description":"Mean cortisol nmol/l during NPH or glargine (Lantus) overnight visit. Hourly cortisol was determined from 22:00 to 8:00.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"380.45","spread":"143.48"},{"groupId":"OG001","value":"388.61","spread":"122.1"}]}]}]},{"type":"SECONDARY","title":"Glucagon","description":"Mean glucagon mcg/l during NPH or glargine (Lantus) overnight visit. Hourly glucagon was determined from 22:00 to 8:00.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.8","spread":"19.0"},{"groupId":"OG001","value":"54.3","spread":"19.0"}]}]}]},{"type":"SECONDARY","title":"Growth Hormone","description":"Mean growth hormone ug/l during NPH or glargine (Lantus) overnight visit. Hourly growth hormone was determined from 22:00 to 8:00.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.09","spread":"1.61"},{"groupId":"OG001","value":"1.27","spread":"2.3"}]}]}]},{"type":"PRIMARY","title":"Blood Glucose","description":"Average value of repeatedly measured absolute values beginning at 22:00, then hourly till 08:00. Participants were monitored during two overnight sampling periods. One overnight was while the participant was on NPH insulin as the long acting insulin; the other overnight was glargine(Lantus) insulin as the the long acting insulin.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":"0.3"},{"groupId":"OG001","value":"7.9","spread":"3.7"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":15},"commonTop":[]}}}